Zacks: Brokerages Expect Clearside Biomedical Inc (CLSD) Will Announce Earnings of -$0.57 Per Share

Wall Street brokerages forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will post earnings per share of ($0.57) for the current quarter, according to Zacks. Zero analysts have made estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.51) and the lowest is ($0.69). Clearside Biomedical posted earnings per share of ($0.54) in the same quarter last year, which suggests a negative year-over-year growth rate of 5.6%. The company is scheduled to announce its next quarterly earnings results on Wednesday, August 8th.

On average, analysts expect that Clearside Biomedical will report full-year earnings of ($2.39) per share for the current fiscal year, with EPS estimates ranging from ($2.88) to ($2.18). For the next financial year, analysts expect that the firm will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.72) to ($1.43). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last announced its quarterly earnings data on Wednesday, May 9th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.05). Clearside Biomedical had a negative net margin of 17,094.20% and a negative return on equity of 131.37%.

Several brokerages recently issued reports on CLSD. ValuEngine raised shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. JMP Securities set a $25.00 price objective on shares of Clearside Biomedical and gave the company a “buy” rating in a research note on Saturday, June 9th. BidaskClub downgraded shares of Clearside Biomedical from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Wedbush reissued an “outperform” rating and set a $29.00 price objective on shares of Clearside Biomedical in a research note on Friday, May 11th. Finally, Needham & Company LLC upped their price objective on shares of Clearside Biomedical from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, March 6th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $20.80.

In related news, Director Gerald D. Cagle purchased 7,500 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was purchased at an average price of $11.89 per share, with a total value of $89,175.00. Following the completion of the transaction, the director now owns 23,441 shares of the company’s stock, valued at approximately $278,713.49. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daniel H. White purchased 11,000 shares of the company’s stock in a transaction that occurred on Monday, June 4th. The shares were bought at an average cost of $9.07 per share, with a total value of $99,770.00. Following the transaction, the insider now directly owns 472,335 shares of the company’s stock, valued at approximately $4,284,078.45. The disclosure for this purchase can be found here. Insiders have purchased 19,000 shares of company stock valued at $194,840 in the last ninety days. 15.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently modified their holdings of CLSD. Sphera Funds Management LTD. increased its position in shares of Clearside Biomedical by 50.0% in the fourth quarter. Sphera Funds Management LTD. now owns 450,000 shares of the company’s stock worth $3,150,000 after acquiring an additional 150,000 shares in the last quarter. Paloma Partners Management Co acquired a new stake in shares of Clearside Biomedical in the fourth quarter worth $124,000. Millennium Management LLC acquired a new stake in shares of Clearside Biomedical in the fourth quarter worth $178,000. Rock Springs Capital Management LP increased its position in shares of Clearside Biomedical by 4.3% in the first quarter. Rock Springs Capital Management LP now owns 975,000 shares of the company’s stock worth $10,462,000 after acquiring an additional 40,000 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Clearside Biomedical in the first quarter worth $161,000. 61.48% of the stock is owned by hedge funds and other institutional investors.

Shares of Clearside Biomedical traded up $0.36, hitting $10.49, on Thursday, according to Marketbeat. 427,515 shares of the stock traded hands, compared to its average volume of 710,926. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.46 and a current ratio of 7.46. The company has a market capitalization of $306.37 million, a price-to-earnings ratio of -4.50 and a beta of -7.22. Clearside Biomedical has a 1 year low of $5.30 and a 1 year high of $15.33.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema.

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply